Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $3.0300 (-2.88%) ($3.0300 - $3.0300) on Thu. Jan. 6, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.65% (three month average) | RSI | 32 | Latest Price | $3.0300(-2.88%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.5% a day on average for past five trading days. | Weekly Trend | HTBX declines -10.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) EEM(53%) VWO(52%) IBUY(51%) ONLN(51%) ARKK(50%) | Factors Impacting HTBX price | HTBX will decline at least -1.825% in a week (0% probabilities). VXX(-44%) VIXM(-41%) UUP(-17%) TLT(-12%) GLD(-7%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.825% (StdDev 3.65%) | Hourly BBV | -1.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-16.56(-646.53%) | Resistance Level | $3.64 | 5 Day Moving Average | $3.19(-5.02%) | 10 Day Moving Average | $3.3(-8.18%) | 20 Day Moving Average | $3.64(-16.76%) | To recent high | -49% | To recent low | 0% | Market Cap | $333m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |